People with BRCA-associated cancer risk or Lynch syndrome may face malignancy at ages that overlap with family-building. The article frames five connected tasks: cancer prevention, fertility consequences of risk-reducing strategies, fertility effects of cancer treatment, effective oncologic therapy, and fertility preservation without compromising cancer outcomes. Its central message is multidisciplinary, individualized decision-making rather than a universal pathway. This is a clinical synthesis, not a comparative trial establishing the best strategy.
Key findings
- BRCA- and Lynch-associated malignancies are uncommon, but diagnosis at younger ages can overlap with reproductive goals.
- Cancer prevention and treatment may affect fertility, so timing, options, and oncologic risk need to be discussed together early in care.
- The authors argue that multidisciplinary care and cautious use of evolving treatments may help reconcile fertility goals with mutation-related cancer risk.
- The abstract provides no pregnancy, recurrence, survival, or comparative-effectiveness estimates, so it cannot establish which specific option works best.
Why this matters globally
The framework is relevant across oncology and reproductive-medicine systems where risk-reducing decisions can alter family-building opportunities. Its practical reach depends on access to genetic services, fertility care, financing, law, and local capacity. It supports shared decision-making but does not guarantee equal safety or effectiveness of fertility preservation in every cancer setting.
Thai researcher contribution
Sarikapan Wilailak of the Faculty of Medicine Ramathibodi Hospital, Mahidol University, is the Thai-affiliated author in the 21-member international team. Thai participation broadens the health-system perspectives represented, although the public records do not specify each author's individual drafting or evidence-review role.
Limitations to consider
The abstract reports no search strategy, selection criteria, risk-of-bias assessment, certainty grading, cohort, or quantitative outcome. BRCA and Lynch syndromes span heterogeneous genes, cancers, stages, ages, and treatments, so general considerations cannot substitute for individual recommendations. Fertility preservation is not suitable for everyone and must not delay necessary cancer care; inherited-variant transmission and embryo testing also require genetic counseling and context-specific ethical review.
Verify the original sources
International Journal of Gynecology & ObstetricsInternational Journal of Gynecology & Obstetrics↗DOI: 10.1002/ijgo.71419